Philip Mack, PhD

Adjunct Professor

  • 4471 Citations
  • 38 h-Index
1995 …2021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 29 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2002 2021


DeGregorio, M., Matthews, D., Felton, J. S., deVere White, R. W., Radke, K., Lloyd, K. K., Gandara, D. R., Beckett, L. A., Gregg, J., Luciw, P. A., Kung, H., Gumerlock, P. H., Mack, P., Evans, C. P., Lara, P. N., Lam, K., Chen, X., Kelly, K., Cherry, S. R., Shacklett, B., Lloyd, K. C. K. & Chen, M.

National Institutes of Health


Project: Research project

Organized Financing
Research Personnel
Clinical Trials
Tumor Biomarkers
Lung Neoplasms
Plasminogen Activator Inhibitor 1

Research Output 1995 2019

Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma

Duan, Z., Chinn, D., Tu, M. J., Zhang, Q. Y., Huynh, J., Chen, J., Mack, P., Yu, A. & Kim, E., Apr 1 2019, In : Translational Oncology. 12, 4, p. 683-692 10 p.

Research output: Contribution to journalArticle

Open Access
Pancreatic Neoplasms
Aurora Kinase A
1 Citation (Scopus)
Open Access
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
13 Citations (Scopus)

Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions

Floc'h, N., Martin, M. J., Riess, J., Orme, J. P., Staniszewska, A. D., Menard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, R. M. V., McKerrecher, D., Cheng, M., Vang, D. P., Burich, R. A., Keck, J. G., Gandara, D. R., Mack, P. & Cross, D. A. E., May 1 2018, In : Molecular Cancer Therapeutics. 17, 5, p. 885-896 12 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Insertional Mutagenesis
2 Citations (Scopus)

A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma

El-Khoueiry, A. B., O'Donnell, R. T., Semrad, T., Mack, P., Blanchard, S., Bahary, N., Jiang, Y., Yen, Y., Wright, J., Chen, H., Lenz, H. J. & Gandara, D. R., Mar 8 2018, (Accepted/In press) In : Cancer Chemotherapy and Pharmacology. p. 1-7 7 p.

Research output: Contribution to journalArticle

Hepatocellular Carcinoma
Liver Neoplasms

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421

Lara, P. N., Plets, M., Tangen, C., Gertz, E., Vogelzang, N. J., Hussain, M., Twardowski, P. W., Garzotto, M. G., Monk, J. P., Carducci, M., Goldkorn, A., Mack, P., Thompson, I., Van Loan, M. & Quinn, D. I., Jan 1 2018, In : Cancer Treatment and Research Communications. 16, p. 18-23 6 p.

Research output: Contribution to journalArticle

bis(2,3,3,3-tetrachloropropyl) ether
Bone Remodeling
Prostatic Neoplasms